The use of the antiprogestin RU486 (mifepristone) as an abortifacient in early pregnancy--clinical and pathological findings; predictive factors for efficacy.

@article{SitrukWare1990TheUO,
  title={The use of the antiprogestin RU486 (mifepristone) as an abortifacient in early pregnancy--clinical and pathological findings; predictive factors for efficacy.},
  author={R{\'e}gine L Sitruk-Ware and Jean Christophe Thalabard and T L de Plunkett and Freddi Lewin and Sylvie Epelboin and Ir{\`e}ne Mowszowicz and H Yaneva and Michel Tournaire and J. Chavini{\'e} and Pierre Mauvais-Jarvis},
  journal={Contraception},
  year={1990},
  volume={41 3},
  pages={221-43}
}
RU486, a potent antiprogesterone steroid was administered to 124 women requesting therapeutic abortion. All were less than 49 days from their last menstrual period. Ten of these subjects (Group I) received high doses of RU486 in a decremental dose regimen (400, 300, 200 and 100 mg/day) over 4 successive days and 14 received 50 mg/day for 7 days (Group II). A further 50 subjects (Group III) received 100 mg/day for seven days and the remaining 50 subjects (Group IV) received 450 mg in a single… CONTINUE READING